Search Results for “EC” – Page 621 – media

Bay Area’s ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene (CELG) And Google (GOOG)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO's lead immunotherapy agent AM0010 in non-small cell lung cancer(NSCLC) and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
- Source: biospace
- 523
- September 13, 2017
immunotherapy Market Views NSCLC pancreatic renal Series
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

After committing billions of dollars to a new hepatitis C cocktail that had the potential to compete with the already deeply entrenched rivals on the market, J&J is calling it quits.
- Source: endpts
- 462
- September 12, 2017
hepatitis Market Views
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 552
- September 12, 2017
asthma Clinical Trials dupilumab Phase
FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to deaths

The US Food and Drug Administration(FDA) has sent a damning warning letter to drug giant Pfizer Inc (NYSE:PFE) after it received “hundreds of complaints” that the anti-allergy EpiPen device misfired “during life-threatening emergencies”.
- Source: Proactiveinvestors
- 691
- September 11, 2017
anti-allergy FDA
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,266
- September 11, 2017
cancer Company Insight T-cell
Teleflex to take over NeoTract for $1.1bn

Teleflex has signed a definitive agreement to purchase NeoTract for approximately $1.1bn. According to the deal, Teleflex will pay $725m worth of cash upfront at closing and up to an additional $375m after the achievement of select commercial milestones associated with sales until the end of 2020.
- Source: medicaldevice-network
- 530
- September 8, 2017
aggrement invasive Market Views
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 739
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
Stent Tek Closes Series A Investment Round for its ePATH AVF Device, Aiming to Improve Vascular Access for Haemodialysis

Stent Tek, a medical device company that is developing a minimally invasive catheter system for dialysis patients, announced today it has successfully closed a Series A funding round with investments from two institutional investors.
- Source: prnewswire
- 579
- September 8, 2017
catheter invasive Market Views Series
47th Meeting of the European Brain Behavior Society (EBBS)

The 47th Meeting of the European Brain Behaviour Society (EBBS) will be held in Bilbao, Spain, on September 8-11, 2017.
- Source: medical-events
- 660
- September 8, 2017
brain Exhibitions & Activities
National Hospitalist Conference

The National Hospitalist Conference will be held in Santa Fe, New Mexico at the Eldorado Hotel & Spa on September 8-10, 2017. The National Hospitalist Conference is designed to provide physicians, physician assistants, and nurse practitioners with information and skills to improve the care of their hospitalized patients.
- Source: medical-events
- 639
- September 8, 2017
Exhibitions & Activities hospitalized

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.